Prognostic Value of the Evolution of HER2-Low Expression after Neoadjuvant Chemotherapy
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose Patients with human epidermal growth factor receptor 2 (HER2)–low advanced breast cancer can benefit from trastuzumab deruxtecan. Given the unclear prognostic characteristics of HER2-low breast cancer, we investigated the prognostic characteristics of HER2-low expression from primary tumor to residual disease after neoadjuvant chemotherapy (NACT). Materials and Methods The data of HER2-negative patients receiving NACT at our center were collected. Pathological complete response (pCR) rate were compared between HER2-0 and HER2-low patients. The evolution of HER2 expression from primary tumor to residual disease and its impact on disease-free survival (DFS) were examined. Results Of the 690 patients, 494 patients had HER2-low status, of which 72.3% were hormone receptor (HR)–positive (p < 0.001). The pCR rates of HER2-low and HER2-0 patients (14.2% vs. 23.0%) showed no difference in multivariate analysis regardless of HR status. No association was observed between DFS and HER2 status. Of the 564 non-pCR patients, 57 (10.1%) changed to HER2-positive, and 64 of the 150 patients (42.7%) with HER2-0 tumors changed to HER2-low. HER2-low (p=0.004) and HR-positive (p=0.010) tumors before NACT were prone to HER2 gain. HER2 gain patients had a better DFS compared with HER2-negative maintained patients (87.9% vs. 79.5%, p=0.048), and the DFS of targeted therapy group was better than that of no targeted therapy group (92.4% vs. 66.7%, p=0.016). Conclusion Although HER2-low did not affect the pCR rate and DFS, significant evolution of HER2-low expression after NACT creates opportunities for targeted therapy including trastuzumab.
Abstract
Purpose Patients with human epidermal growth factor receptor 2 (HER2)–low advanced breast cancer can benefit from trastuzumab deruxtecan. Given the unclear prognostic characteristics of HER2-low breast cancer, we investigated the prognostic characteristics of HER2-low expression from primary tumor to residual disease after neoadjuvant chemotherapy (NACT). Materials and Methods The data of HER2-negative patients receiving NACT at our center were collected. Pathological complete response (pCR) rate were compared between HER2-0 and HER2-low patients. The evolution of HER2 expression from primary tumor to residual disease and its impact on disease-free survival (DFS) were examined. Results Of the 690 patients, 494 patients had HER2-low status, of which 72.3% were hormone receptor (HR)–positive (p < 0.001). The pCR rates of HER2-low and HER2-0 patients (14.2% vs. 23.0%) showed no difference in multivariate analysis regardless of HR status. No association was observed between DFS and HER2 status. Of the 564 non-pCR patients, 57 (10.1%) changed to HER2-positive, and 64 of the 150 patients (42.7%) with HER2-0 tumors changed to HER2-low. HER2-low (p=0.004) and HR-positive (p=0.010) tumors before NACT were prone to HER2 gain. HER2 gain patients had a better DFS compared with HER2-negative maintained patients (87.9% vs. 79.5%, p=0.048), and the DFS of targeted therapy group was better than that of no targeted therapy group (92.4% vs. 66.7%, p=0.016). Conclusion Although HER2-low did not affect the pCR rate and DFS, significant evolution of HER2-low expression after NACT creates opportunities for targeted therapy including trastuzumab.
참고문헌 (31)
- Wolff AC, "Human epidermal growth factor receptor 2 testing in breast cancer : American Society of Clinical Oncology", College of American Pathologists clinical practice guideline focused update, 2018, pp.36, 2105~2122
- Piccart M, "Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer in the APHINITY trial : 6 years’ follow-up", J Clin Oncol, 39, pp.1448~1457 (2021)
- Swain SM, "Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer(CLEOPATRA) : end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study", Lancet Oncol, 21, pp.519~530 (2020)
- Fehrenbacher L, "NSABP B-47", NRG oncology phase III randomized trial comparing adjuvant chemotherapy with or without trastuzumab in high-risk invasive breast cancer negative for HER2 by FISH and with IHC 1+ or 2, 2020, pp.38, 444~453
- Tarantino P, "HER2-low breast cancer : pathological and clinical landscape", J Clin Oncol, 38, pp.1951~1962 (2020)
- Schalper KA, "A retrospective population-based comparison of HER2 immunohistochemistry and fluorescence in situ hybridization in breast carcinomas : impact of 2007 American Society of Clinical Oncology", College of American Pathologists criteria, 2014, pp.138, 213~219
- Banerji U, "Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer : a phase 1 dose-escalation and dose-expansion study", Lancet Oncol, 20, pp.1124~1135 (2019)
- Modi S, "Antitumor activity and safety of trastuzumab deruxtecan in patients with HER2-low-expressing advanced breast cancer : results from a phase Ib study", J Clin Oncol, 38, pp.1887~1896 (2020)
- Modi S, "Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer", N Engl J Med, 387, pp.9~20 (2022)
- Schettini F, "Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer", NPJ Breast Cancer, 7, pp.1~ (2021)
- Zhang G, "Distinct clinical and somatic mutational features of breast tumors with high-, low-, or non-expressing human epidermal growth factor receptor 2 status", BMC Med, 20, pp.142~ (2022)
- Denkert C, "Clinical and molecular characteristics of HER2-low-positive breast cancer : pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials", Lancet Oncol, 22, pp.1151~1161 (2021)
- Tarantino P, "Prognostic and biologic significance of ERBB2-low expression in early-stage breast cancer", JAMA Oncol, 8, pp.1177~1183 (2022)
- Bao KK, "The Association of ERBB2-low expression with the efficacy of cyclin-dependent kinase 4", 6 inhibitor in hormone receptor-positive, ERBB2-negative metastatic breast cancer, 2021, pp.4, e2133132~
- de Nonneville A, "Pathological complete response rate and disease-free survival after neoadjuvant chemotherapy in patients with HER2-low and HER2-0 breast cancers", Eur J Cancer, 176, pp.181~188 (2022)
- Gahlaut R, "Effect of neoadjuvant chemotherapy on breast cancer phenotype, ER", PR and HER2 expression : implications for the practising oncologist, 2016, pp.60, 40~48
- Niikura N, "Changes in tumor expression of HER2 and hormone receptors status after neoadjuvant chemotherapy in 21, 755 patients from the Japanese breast cancer registry", Ann Oncol, 27, pp.480~487 (2016)
- Miglietta F, "HER2-low-positive breast cancer : evolution from primary tumor to residual disease after neoadjuvant treatment", NPJ Breast Cancer, 8, pp.66~ (2022)
- Won HS, "Clinical significance of HER2-low expression in early breast cancer : a nationwide study from the Korean Breast Cancer Society", Breast Cancer Res, 24, pp.22~ (2022)
- Horisawa N, "The frequency of low HER2 expression in breast cancer and a comparison of prognosis between patients with HER2-low and HER2-negative breast cancer by HR status", Breast Cancer, 29, pp.234~241 (2022)
- Fernandez AI, "Examination of low ERBB2 protein expression in breast cancer tissue", JAMA Oncol, 8, pp.1~4 (2022)
- Villegas SL, "Therapy response and prognosis of patients with early breast cancer with low positivity for hormone receptors : an analysis of 2765 patients from neoadjuvant clinical trials", Eur J Cancer, 148, pp.159~170 (2021)
- Kang S, "Pathological complete response, long-term outcomes, and recurrence patterns in HER2-low versus HER2-zero breast cancer after neoadjuvant chemotherapy", Eur J Cancer, 176, pp.30~40 (2022)
- Guven DC, "HER2-low breast cancer could be associated with an increased risk of brain metastasis", Int J Clin Oncol, 27, pp.332~339 (2022)
- Osborne CK, "Mechanisms of endocrine resistance in breast cancer", Annu Rev Med, 62, pp.233~247 (2011)
- Arpino G, "Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family : molecular mechanism and clinical implications for endocrine therapy resistance", Endocr Rev, 29, pp.217~233 (2008)
- Mutai R, "Prognostic impact of HER2-low expression in hormone receptor positive early breast cancer", Breast, 60, pp.62~69 (2021)
- Almstedt K, "Long-term prognostic significance of HER2-low and HER2-zero in node-negative breast cancer", Eur J Cancer, 173, pp.10~19 (2022)
- Tarantino P, "Evolution of low HER2 expression between early and advanced-stage breast cancer", Eur J Cancer, 163, pp.35~43 (2022)
- Miglietta F, "Evolution of HER2-low expression from primary to recurrent breast cancer", NPJ Breast Cancer, 7, pp.137~ (2021)
- Yoshida A, "Change in HER2 status after neoadjuvant chemotherapy and the prognostic impact in patients with primary breast cancer", J Surg Oncol, 116, pp.1021~1028 (2017)